HASBROUCK HEIGHTS, N.J., November 14 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) announced today completion of a large new 2 year
follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study
evaluated symptomatic progress of over one hundred subjects involved in the
Company's Phase 2 U.S. clinical trial initiated in 2005. Individuals in the
study were assessed 2 years after NX-1207 treatment for symptomatic
improvement, treatment outcomes, and durability of efficacy. This is the
largest cohort of patients treated with NX-1207 followed for as long as 2
years thus far. The Company expects to report the results of the follow-up
study in the next 2 weeks once final analysis of the data is completed.
NX-1207 has successfully completed three U.S. trials and several smaller
long term follow-up studies to date. The company's Phase 2 double-blind,
placebo controlled, randomized study showed positive efficacy and safety
results for NX-1207 after 3 months in patients with BPH. Overall, patients
treated with NX-1207 showed after 3 months a mean improvement of 9.35 points
in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and
treatments. This improvement compares favorably to the 3.5 to 5 points
reported in published studies of currently approved drugs for BPH and reached
statistical significance when compared to placebo. Subjects treated with
NX-1207 also showed an overall significant reduction in mean prostate volume.
The results of the trial demonstrated the excellent safety and side effect
profile of NX-1207. Subjects treated with NX-1207 had no serious side effects.
In particular, patients given NX-1207 had no (0%) significant sexual side
BPH afflicts approximately half of men over age 50 and close to 90% of
men by age 80. The disorder causes difficulties with urination associated with
aging, such as urination at night, urge to void frequently, hesitancy, weak
stream, and other problems.
More information about Nymox is available at www.nymox.com, email:
email@example.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products involve
substantial risks and uncertainties and actual results may differ materially
from expectations. Promising early results do not ensure that later stage or
larger scale clinical trials will be successful or will proceed as expected.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,